Legal, Regulatory, and Practical Issues to Consider When Adopting Decentralized Clinical Trials: Recommendations From the Clinical Trials Transformation Initiative.

Mobile clinical trials Mobile medical applications Mobile nursing Mobile technology Participant-centric trials Telehealth

Journal

Therapeutic innovation & regulatory science
ISSN: 2168-4804
Titre abrégé: Ther Innov Regul Sci
Pays: Switzerland
ID NLM: 101597411

Informations de publication

Date de publication:
07 2020
Historique:
received: 20 05 2019
accepted: 17 09 2019
entrez: 20 6 2020
pubmed: 20 6 2020
medline: 29 5 2021
Statut: ppublish

Résumé

Traditional clinical trials are often expensive, inefficient, include selected populations, and can create significant participant burden via travel and other logistical demands. Using new technologies and methodologies to promote a decentralized approach has the potential to improve the efficiency of clinical trials. The Clinical Trials Transformation Initiative (CTTI)-a public-private partnership to improve clinical trials-launched a multi-stakeholder Decentralized Clinical Trials (DCTs) Project to provide recommendations on addressing the actual and perceived legal, regulatory, and practical challenges with DCT design and conduct in the United States. Informed by qualitative group interviews and an expert meeting, CTTI engaged stakeholders to identify key challenges to implementing DCTs and possible solutions. The CTTI DCT project team used the interview findings and expert feedback to develop recommendations that will drive broader use of DCTs. CTTI's recommendations cover protocol design, use of telemedicine and mobile healthcare providers, medical product supply chain, investigator delegation and oversight, and safety monitoring considerations. By implementing these recommendations, sponsors, contract research organizations, and others can help advance successful medical product development using mobile technologies and methodologies in DCTs.

Sections du résumé

BACKGROUND
Traditional clinical trials are often expensive, inefficient, include selected populations, and can create significant participant burden via travel and other logistical demands. Using new technologies and methodologies to promote a decentralized approach has the potential to improve the efficiency of clinical trials. The Clinical Trials Transformation Initiative (CTTI)-a public-private partnership to improve clinical trials-launched a multi-stakeholder Decentralized Clinical Trials (DCTs) Project to provide recommendations on addressing the actual and perceived legal, regulatory, and practical challenges with DCT design and conduct in the United States.
METHODS
Informed by qualitative group interviews and an expert meeting, CTTI engaged stakeholders to identify key challenges to implementing DCTs and possible solutions.
RESULTS
The CTTI DCT project team used the interview findings and expert feedback to develop recommendations that will drive broader use of DCTs.
CONCLUSIONS
CTTI's recommendations cover protocol design, use of telemedicine and mobile healthcare providers, medical product supply chain, investigator delegation and oversight, and safety monitoring considerations. By implementing these recommendations, sponsors, contract research organizations, and others can help advance successful medical product development using mobile technologies and methodologies in DCTs.

Identifiants

pubmed: 32557302
doi: 10.1007/s43441-019-00006-4
pii: 10.1007/s43441-019-00006-4
pmc: PMC7362888
doi:

Types de publication

Journal Article Randomized Controlled Trial Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

779-787

Références

Telemed J E Health. 2013 Jun;19(6):444-54
pubmed: 23697504
Int J Technol Assess Health Care. 2010 Apr;26(2):149-55
pubmed: 20392317
Am J Psychiatry. 2004 Aug;161(8):1471-6
pubmed: 15285975
Clin Trials. 2018 Feb;15(1_suppl):13-18
pubmed: 29452520
J Eur Acad Dermatol Venereol. 2018 Feb;32(2):215-224
pubmed: 28516492
World J Psychiatry. 2015 Sep 22;5(3):286-304
pubmed: 26425443
J Gen Intern Med. 2007 Aug;22(8):1086-93
pubmed: 17492326
Telemed J E Health. 2006 Jun;12(3):341-50
pubmed: 16796502
Neurosurg Focus. 2014 Jan;36(1):E4
pubmed: 24380481
Curr Dermatol Rep. 2016;5:96-104
pubmed: 27182461
JAMA Dermatol. 2015 Feb;151(2):154-60
pubmed: 25338198

Auteurs

Maria Apostolaros (M)

Pharmaceutical Research and Manufacturers of America (PhRMA), 950 F Street NW, Suite 300, Washington, DC, 20004, USA.

David Babaian (D)

Advarra Consulting, 1501 Fourth Ave, Suite 800, Seattle, WA, 98101, USA.

Amy Corneli (A)

Clinical Trials Transformation Initiative, 200 Morris St, Durham, NC, 27701, USA.
Department of Population Health Sciences, Duke Clinical Research Institute, 215 Morris St, Suite 210, Durham, NC, 27701, USA.

Annemarie Forrest (A)

Clinical Trials Transformation Initiative, 200 Morris St, Durham, NC, 27701, USA. annemarie.forrest@duke.edu.

Gerrit Hamre (G)

Hamre Strategies LLC, 507 N Elizabeth St, Durham, NC, 27701, USA.

Jan Hewett (J)

Office of Compliance, Center for Drug Evaluation and Research, Food and Drug Administration, New Hampshire Ave, Building 51, Silver Spring, MD, 20903, USA.

Laura Podolsky (L)

Science 37, Inc., 12121 Bluff Creek Dr, Suite 100, Los Angeles, CA, 90094, USA.

Vaishali Popat (V)

Center for Drug Evaluation and Research, Office of New Drugs, Food and Drug Administration, New Hampshire Ave, Building 22, Silver Spring, MD, 20903, USA.

Penny Randall (P)

IQVIA, 10188 Telesis Court, Suite 400, San Diego, CA, 92121, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH